Ge Long Hui·2026-03-30 16:45Core Viewpoint - 康龙化成 reported a revenue of 14.095 billion RMB for the year ending December 31, 2025, representing a year-on-year growth of 14.82%, while the net profit attributable to shareholders decreased by 7.2% to 1.664 billion RMB [1] Group 1: Financial Performance - The company's revenue for the fiscal year was 14.095 billion RMB, showing a growth of 14.82% compared to the previous year [1] - The net profit attributable to shareholders was 1.664 billion RMB, which is a decrease of 7.2% year-on-year [1] - The board proposed a final dividend of 2.0 RMB per 10 shares (before tax) for the year ending December 31, 2025 [1] Group 2: Strategic Initiatives - The company is deepening its customer-centric service philosophy and leveraging a fully integrated service platform to meet diverse global client needs [1] - Significant achievements were noted in expanding strategic customer relationships, particularly with large pharmaceutical companies [1] - The company is actively implementing market strategies tailored to the Chinese market, resulting in rapid growth in client business [1] Group 3: Future Outlook - The company expects a year-on-year growth of over 14% in new signed orders for 2025 [1] - Based on new orders and business trends, the company anticipates a revenue growth of 12% to 18% for the year 2026 [1]